Related Experiment Video
Updated: Mar 12, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells
Madhavi Gangapuram1, Riccardo Jean1, Elizabeth Mazzio1
1College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, U.S.A.
Abstract:
Triple-negative breast cancer (TNBC) occurs at greater frequency amongst African-Americans, being characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal receptor 2 (HER2). TNBC is often invasive and typically treated with cytostatic agents such as taxanes in combination with anthracyclines or platinum-based drugs. In this study, we synthesized a number of tetrahydroisoquinoline moieties by N-amination of substituted isoquinolines by O-mesytelene sulfonylhydroxylamine followed by ylide formation and reduction, which yielded the desired, substituted tetrahydroisoquinolines (THIQs) in moderate to good yield. Using a differential scatter plot to identify potential selective ER-modulating drugs in ER-positive control cells (MCF-7) driven by estradiol vs. TNBC (MDA-MB-231) cells, the in vitro data showed an absence of effects on the ER (compared to 4-hydroxytamoxifen and raloxifene). In contrast, two lead compounds halted proliferation (cytostatic) in MDA-MB-231 TNBC cells at a potency level below 2.5 μM concomitant with mitotic arrest, attenuated replicative DNA synthesis, halted microtubule nucleation/stunted tubulin polymerization, abnormal expansive cytoskeletal tubulin and actin morphologies with multinucleation of cells. The most effective cytostatic compounds GM-4-53 and GM-3-121 blocked replicative processes at the G2 growth phase. These findings suggest that specific THIQs work independently of the ER, by holding static the microtubule network thereby preventing mitosis. Future work is required to establish the safety and efficacy of these drugs and their potential adjunct therapeutic gain in the presence of taxanes in TNBC.
Insights
New tetrahydroisoquinoline (THIQ) compounds show promise as triple-negative breast cancer (TNBC) therapeutics. These THIQs halt TNBC cell proliferation by disrupting microtubule networks, independent of hormone receptors.
Area of Science:
- Medicinal Chemistry
- Oncology
- Cell Biology
Background:
- Triple-negative breast cancer (TNBC) disproportionately affects African-Americans and lacks targeted therapies.
- Current TNBC treatments include cytotoxic agents, but novel therapeutic strategies are needed.
- Tetrahydroisoquinolines (THIQs) are a class of compounds with potential pharmacological activity.
Purpose of the Study:
- To synthesize novel substituted tetrahydroisoquinoline (THIQ) moieties.
- To evaluate the in vitro efficacy of synthesized THIQs against triple-negative breast cancer (TNBC) cells.
- To elucidate the mechanism of action of promising THIQ compounds in TNBC.
Main Methods:
- Synthesis of THIQs via N-amination of substituted isoquinolines, followed by ylide formation and reduction.
- In vitro evaluation using differential scatter plots to assess ER modulation in MCF-7 and MDA-MB-231 cells.
- Assays to determine antiproliferative effects, cell cycle arrest (G2 phase), DNA synthesis inhibition, and microtubule dynamics.
Main Results:
- Successful synthesis of substituted THIQs in moderate to good yields.
- Two lead THIQ compounds (GM-4-53 and GM-3-121) exhibited potent cytostatic effects on TNBC cells (MDA-MB-231) with IC50 < 2.5 μM.
- These compounds induced mitotic arrest, inhibited DNA replication, disrupted microtubule polymerization, and caused multinucleation, acting independently of the estrogen receptor (ER).
Conclusions:
- Specific THIQs possess significant antiproliferative activity against TNBC cells.
- The mechanism involves direct interference with microtubule dynamics, leading to cell cycle arrest at the G2 phase.
- THIQs represent a potential new class of ER-independent therapeutics for TNBC, warranting further investigation for safety and efficacy, including combination therapy with taxanes.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Destabilization of Microtubules
Microtubule Instability
Microtubule Formation
Inhibition of Cdk Activity